Literature DB >> 24215052

Langerhans cell sarcoma of the nasopharynx: a rare case.

M Keklik1, S Sivgin, O Kontas, U Abdulrezzak, L Kaynar, M Cetin.   

Abstract

Langerhans cell sarcoma, a tumour with markedly malignant cytological features that originates from Langerhans cells, is a very rare disease. We report the first case of 39-year-old male with Langerhans cell sarcoma arising in the nasopharynx. We chose the 2-chlorodeoxyadenosine (2-CDA) regimen as first-line chemotherapy, and clinical improvement of Langerhans cell sarcoma was obtained. After the fourth cycle of 2-CDA therapy, however, disease progression was observed, and we administered ESHAP regimen (etoposide, carboplatin, cytarabine, methylprednisolone) as a second-line therapy. After we administered two cycles of ESHAP, however, the patient developed aggressive progression and he died. The importance of immunohistochemical findings is obvious in Langerhans cell sarcoma diagnosis. Considering that Langerhans cell sarcoma behaves in a very malignant fashion, a more aggressive treatment approach is necessary for patients with Langerhans cell sarcoma.

Entities:  

Keywords:  2-CDA; ESHAP; Langerhans cell sarcoma; nasopharynx

Mesh:

Substances:

Year:  2013        PMID: 24215052     DOI: 10.1177/0036933013508046

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  3 in total

1.  Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review.

Authors:  Yaonan Zhang; Zongyang Qu; Fang Fang
Journal:  Oncol Lett       Date:  2016-09-27       Impact factor: 2.967

2.  Langerhans cell sarcoma arising from antecedent langerhans cell histiocytosis: A case report.

Authors:  Wu Yi; Wan-Yuan Chen; Tian-Xin Yang; Jian-Ping Lan; Wen-Na Liang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

3.  Epstein-Barr Virus-Positive Langerhans Cell Sarcoma: Is There a Link? A Case Report.

Authors:  Yu Guo; Shui-Hong Zhou; Zai-Zai Cao; Yang-Yang Bao; Li-Fang Shen; Hong-Tian Yao
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.